Prot #NKT2152-202: A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination with Palbociclib (Doublet) and with Palbociclib and Sasanlimab (Triplet) in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Project: Research project

Status	Active
Effective start/end date	11/1/23 → 11/1/26

Pharmaceutical Research Associates, Inc. (Prot# NKT2152-202 // Prot# NKT2152-202)
NiKang Therapeutics, Inc. (Prot# NKT2152-202 // Prot# NKT2152-202)

Project Details